What is the difference between Lamisil and Miconazole?
By
Dr Natalia Marceli Stephanes (PhD)
Author bio
Dr Natália Marcéli Stephanes PhD is a Pharmacist with expertise in Drugs Administration and Toxicity; Discovery of New Drugs; Cancer Treatment; Biochemical Analyzes and Hematological Analyzes. She writes and reviews content on these topics.
Dr Natália Marcéli Stephanes’ Highlights:
- Pharmacist at the Department of Health of Santa Catarina State, Brazil
- PhD with a focus on oncology treatment
- Years of experience in commercial pharmacy
- Bachelor, Master and PhD degrees in Pharmacy at the Federal University of Santa Catarina
Professional Experience:
From her undergraduate studies to her Master’s and Doctorate degrees in Pharmacy, Dr Natália Marcéli Stephanes has participated in numerous scientific studies in the field of oncology and onco-hematology at the University Hospital of the Federal University of Santa Catarina, Brazil. Her research has focused on understanding the molecular and biochemical bases of malignant neoplasms and investigating safer and more effective therapeutic alternatives.
Dr Natália Marcéli Stephanes has also served as an assistant professor of haematology for undergraduate students at the Federal University of Santa Catarina. Additionally, she held the position of professor of Hospital Pharmacy at the Qualificar Technical School in Brazil, where she developed instructional materials for use in the Pharmacy Postgraduate Program at the Leonardo Da Vinci University Center.
In addition to her academic experiences, Dr Natália Marcéli Stephanes possesses a strong expertise in commercial pharmacy, with in-depth knowledge of medications, their routes of administration, desired effects, adverse effects, and toxicity.
Currently, Dr Natália Marcéli Stephanes works as a Pharmacist at the Health Department of Santa Catarina State, where her role entails providing pharmaceutical scientific consulting services to judges.
Education:
- 2016 Bachelor in Pharmacy at the Federal University of Santa Catarina, Brazil
- 2018 Master in Pharmacy at the Federal University of Santa Catarina, Brazil
- 2023 PhD in Pharmacy at the Federal University of Santa Catarina, Brazil
The main publications of Dr Natália Marcéli Stephanes are:
Falchetti M ; Delgobo M, Zancanaro H, Almeida K, Das Neves RN, Dos Santos B, Stefanes NM, et al. Bishop Omics-based identification of an NRF2-related auranofin resistance signature in cancer: Insights into drug repurposing. Comput. Biol. Med [Internet]. 2023; 152:106347.
Feuser PM, Matos dos Santos PC, Cordeiro AP, Stefanes NM, Walter LO, Maioral MF, Santos-Silva MC, et al. Antineoplastic activity of free 4-nitrochalcone and encapsulated in poly(thioether-ester) nanoparticles obtained by thiol-ene polymerization in two human leukemia cell lines (Jurkat and K562). J Drug Deliv Sci Technol [Internet]. 2022; 67:102924.
Jacques AV, Stefanes NM, Walter LO, Perondi DM, Efe FL, Souza LFS, Sens L, et al. Synthesis of chalcones derived from 1-naphthylacetophenone and evaluation of their cytotoxic and apoptotic effects in acute leukemia cell lines. Bioorg. Chem [Internet]. 2021; 116:105315.
Duarte BF, Vieira DSC, Lisboa ML, Stefanes NM, Grando LJ, Santos-Silva MC. Características clínico-epidemiológicas de pacientes portadores de carcinoma de células escamosas de boca. Arquivos Catarinenses de Medicina. 2021; 50(2): 232–245.
Machado V, Jacques AV, Stefanes NM, Santos-Silva MC, Biavatti MW. Anti-leukemic activity of semisynthetic derivatives of Lupeol. Nat. Prod. Res. 2021; 35(22):4494-4501.
Bigolin A, Maioral MF, Stefanes NM, Mascarello A, Chiaradia-Delatorre LD, Nunes RJ, Yunes RA, et al. A novel sulfonamide derivative as a strong and selective apoptotic agent against hematological malignancies. Chem. Pap. 2020; 74:2965–2976.
Bigolin A, Maioral MF, Stefanes NM, Zatelli GA, Philippus AC, Falkenberg MB, Santos-Silva MC. Cytotoxic mechanisms of primin, a natural quinone isolated from Eugenia hiemalis, on hematological cancer cell lines. Anticancer Drugs. 2020; 31(7):709-717.
Maioral MF, Stefanes NM, Neufeldt PD, Chiaradia-Delatorre LD, Nunes RJ, Santos-Silva MC. Aldehyde biphenyl chalcones induce immunogenic apoptotic-like cell death and are promising new safe compounds against a wide range of hematologic cancers. Future Med. Chem. 2020; 12(8):673–688.
Perondi DM, Jacques AV, Stefanes NM, Maioral MF, Sens L, Pacheco LA, Cury NM, et al. A novel thiosemicarbazone as a promising effective and selective compound for acute leukemia. Anticancer Drugs. 2019; 30(8):p 828-837.
Rengifo AFC, Stefanes NM, Toigo J, Mendes C, Argenta DF, Dotto MER, Santos-Silva MC, et al. PEO-chitosan nanofibers containing carboxymethyl-hexanoyl chitosan/dodecyl sulfate nanoparticles loaded with pyrazoline for skin cancer treatment. Eur. Polym. J. 2019; 119:335-343.
Rengifo AFC, Stefanes NM, Toigo J, Mendes C, Santos-Silva MC, Nunes RJ, Parize AL, et al. A new and efficient carboxymethyl-hexanoyl chitosan/dodecyl sulfate nanocarrier for a pyrazoline with antileukemic activity. Mater. Sci. Eng. C [Internet]. 2019; 105:110051.
Maioral MF, Stefanes NM, Bigolin A, Zatelli GA, Philippus AC, Falkenberg MB, Santos-Silva MC. Miconidine acetate, a new selective and cytotoxic compound with synergic potential, induces cell cycle arrest and apoptosis in leukemia cells. Invest. New Drugs. 2019; 37:912–922.
Srefanes NM, Toigo J, Maioral MF, Jacques AV, Chiaradia-Delatorre LD, Perondi DM, Ribeiro AAB, et al. Synthesis of novel pyrazoline derivatives and the evaluation of death mechanisms involved in their antileukemic activity. Bioorg. Med. Chem. 2019; 27(2):375-382.
Maioral MF, Bodack CN, Stefanes NM, Bigolin A, Mascarello A, Chiaradia-Delatorre LD, Yunes RA, et al. Cytotoxic effect of a novel naphthylchalcone against multiple cancer cells focusing on hematologic malignancies. Biochim. 2017; 140:48-57.
You can view some of Dr Natália’s work below and links to her professional profile below.
Research Gate: https://www.researchgate.net/profile/Natalia-Stephanes
Linkedin: https://www.linkedin.com/in/nataliamarceli/
What is the difference between Lamisil and Miconazole?
Lamisil and Miconazole are different anti-fungal medications, with different mechanisms of action and side effect profiles. The key differences between Lamisil and Miconazole include:
Mechanism of action
Lamisil is classified as an allylamine antifungal, while Miconazole belongs to the imidazole antifungal group. Lamisil works by inhibiting an enzyme called squalene epoxidase, which is essential for the synthesis of ergosterol, a crucial component of the fungal cell membrane (1).
By disrupting the fungal cell membrane, Lamisil effectively kills the fungi and treats the infection.
On the other hand, Miconazole and similar drugs like Ketoconazole work by inhibiting the synthesis of ergosterol and disrupting the fungal cell membrane, leading to cell death (2).
Uses
Lamisil is commonly used to treat various fungal infections of the skin, such as athlete’s foot, jock itch, and ringworm. It is also available in oral form to treat fungal nail infections (onychomycosis). (1) Lamisil is different from other drugs that can be used for similar infections, like clotrimazole.
Miconazole, on the other hand, is considered more effective for vaginal infections and the duration of treatment is relatively shorter. (2)
Available dosage forms
Another difference between the two medications is that Lamisil is available in topical as well as oral formulations (1).
Miconazole, on the other hand, is available as a topical formulation and is effective against yeast infections, for which Lamisil is not considered an effective choice. (2)
Side effect profiles
Both Lamisil and Miconazole may cause side effects, although they can vary in type and severity. Common side effects of Lamisil include skin irritation, itching, and burning at the application site. In some cases, it may cause more systemic side effects such as headache, diarrhoea, or taste disturbances (1).
Miconazole, when used topically, can also cause skin irritation and itching. When used vaginally, it may lead to temporary burning or discomfort. (2)
Effectiveness
The effectiveness of both medications can vary depending on the type and severity of the fungal infection. Lamisil is generally considered to be more effective for treating nail fungal infections due to its ability to penetrate the nails and reach the site of infection (1).
Miconazole, on the other hand, is highly effective against superficial skin infections and yeast infections. (2)
It’s essential to use these medications as directed by your healthcare provider or as indicated on the product label. If symptoms persist or worsen, or if you experience any concerning side effects, it’s crucial to seek medical advice right away.
How to choose between Lamisil and Miconazole?
When it comes to choosing between Lamisil and Miconazole, it’s essential to rely on your doctor’s expertise and advice. Your healthcare provider will consider various factors, such as the type and severity of your fungal infection, your medical history, any allergies you may have, and other medications you are taking
Your doctor will ensure that the chosen antifungal medication is safe and effective for your particular situation. They will provide you with clear instructions on how to use the medication correctly, including the proper dosage and duration of treatment.
Following your doctor’s guidance is crucial to ensure the best possible outcome and to avoid any potential side effects or complications.
Was this helpful?
References
1.-
Maxfield L, Preuss CV, Bermudez R. Terbinafine. 2023 May 29. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan–. PMID: 31424802. https://www.ncbi.nlm.nih.gov/books/NBK545218
2.-
Sawyer PR, Brogden RN, Pinder RM, Speight TM, Avery GS. Miconazole: a review of its antifungal activity and therapeutic efficacy. Drugs. 1975;9(6):406-23. doi: 10.2165/00003495-197509060-00002. PMID: 1149649. https://pubmed.ncbi.nlm.nih.gov/1149649/
